跳至主要内容
临床试验/NCT04472078
NCT04472078已完成不适用

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) in a Vulnerable Neighbourhood, Buenos Aries Argentina

Hospital Italiano de Buenos Aires1 个研究点 分布在 1 个国家目标入组 873 人开始时间: 2020年6月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
873
试验地点
1
主要终点
to establish the seroprevalence of SARS-CoV-2

研究概览

简要总结

Background The study aimed to establish the seroprevalence of SARS-COV-2 in an Argentinian slum three months after the first case was reported.

Methods Between June 10th and July 1st, a cross-sectional design was carried out on people over 14 years old, selected from a probabilistic sample of households. Finger prick puncture ELISA test

详细描述

A community-level seroprevalence survey was conducted in a cross-sectional design during a Participatory Action Research (PAR).

Starter PAR team: researcher who developed the Elisa Test, virologist that perform the analysis of the test and physician that served as volunteer field epidemiologist at the surveillance system (DetectAr Barrio 31) offered technical cooperation to test people experiencing homelessness.

PAR-First step: A sample for convenience of homeless people was tested during 3 days in a popular dining room managed by a non-governmental organization. Samples were collected by a DetectAr nurse and a volunteer epidemiologist.

PAR-Second step: feasibility was determined by the DetectAr coordinators of the Community Health Division of the Ministry of Health and the 12 health community workers (HCWs) when two volunteer epidemiologists from a University Institute explained the field organization (sample technique, data collection and database entry) for obtaining a probabilistic sample of residents. The PAR process was a cornerstone for reaching the sample size.

PAR-Third step: A cross-sectional study for seroprevalence survey was carried out.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All subjects of 14 years or more who accept to be test

排除标准

  • 未提供

结局指标

主要结局

to establish the seroprevalence of SARS-CoV-2

时间窗: up to 20 weeks

Prevalence of positive IgG for SARS-CoV-2

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ALICIA MISTCHENKO

Principal Investigator

Hospital de Niños R. Gutierrez de Buenos Aires

研究点 (1)

Loading locations...

相似试验